Form 4: Artiva Biotherapeutics Insider Buys Shares

Sentiment:

Insider Transaction (Form 4)


Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 16, 2026.

Summary

  • Open-market purchase: acquired 152,472 Common Stock at $8.93 ($1,361,575) on July 16, 2026; holds 16,970,045 after (Indirect).
  • Open-market purchase: acquired 7,882 Common Stock at $8.95 ($70,544) on July 17, 2026; holds 16,977,927 after (Indirect).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $1,432,119, committing personal capital to the stock.

Insider Transactions

Ra Capital Management, L.P. — Director, 10% owner

RA Capital Healthcare Fund LP — Director, 10% owner

RA Capital Nexus Fund, L.P. — Director

RA Capital Nexus Fund III, L.P. — Director

Peter Kolchinsky — Director, 10% owner

Rajeev M. Shah — Director, 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-07-16Open-market purchaseCommon Stock152,472$9$1.4M16,970,045
2026-07-17Open-market purchaseCommon Stock7,882$9$70.5K16,977,927

Key Dates

DateDescription
2026-07-16Open-market purchase (152,472 shares)
2026-07-17Open-market purchase (7,882 shares)

Keywords

insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., bullish, Ra Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Peter Kolchinsky, Rajeev M. Shah

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.